{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:15:13Z","timestamp":1794946513415,"version":"4.9.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Symptomatic burden in myeloproliferative neoplasms is present in most patients and compromises quality of life. We sought to validate a broadly applicable 18-item instrument (Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF], coadministered with the Brief Fatigue Inventory) to assess symptoms of myelofibrosis, essential thrombocythemia, and polycythemia vera among prospective cohorts in the United States, Sweden, and Italy. A total of 402 MPN-SAF surveys were administered (English [25%], Italian [46%], and Swedish [28%]) in 161 patients with essential thrombocythemia, 145 patients with polycythemia vera, and 96 patients with myelofibrosis. Responses among the 3 administered languages showed great consistency after controlling for MPN subtype. Strong correlations existed between individual items and key symptomatic elements represented on both the MPN-SAF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Enrolling physicians' blinded opinion of patient symptoms (6 symptoms assessed) were highly correlated with corresponding patients' responses. Serial administration of the English MPN-SAF among 53 patients showed that most MPN-SAF items are well correlated (r &gt; 0.5, P &lt; .001) and highly reproducible (intraclass correlation coefficient &gt; 0.7). The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.<\/jats:p>","DOI":"10.1182\/blood-2011-01-328955","type":"journal-article","created":{"date-parts":[[2011,5,2]],"date-time":"2011-05-02T21:57:49Z","timestamp":1304373469000},"page":"401-408","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":286,"title":["The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients"],"prefix":"10.1182","volume":"118","author":[{"given":"Robyn","family":"Scherber","sequence":"first","affiliation":[{"name":"Rosalind Franklin School of Medicine, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[{"name":"Section of Biostatistics, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johansson","sequence":"additional","affiliation":[{"name":"Internal Medicine, NU Hospital Organization, Uddevalla, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Hematology, Department of Medical and Surgical Care, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Andreasson","sequence":"additional","affiliation":[{"name":"Internal Medicine, NU Hospital Organization, Uddevalla, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Ferarri","sequence":"additional","affiliation":[{"name":"Biolology Science, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Samuelsson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karolinska Institutet, Stockholm South Hospital, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Birgegard","sequence":"additional","affiliation":[{"name":"Department of Hematology, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Radia","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111808350836800_B1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients.","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"13","key":"2019111808350836800_B2","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111808350836800_B3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111808350836800_B4","article-title":"Durable responses with the JAK1\/JAK2 Inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU) [abstract].","volume":"116","author":"Verstovsek","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111808350836800_B5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"2019111808350836800_B6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111808350836800_B7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"2019111808350836800_B8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.","volume":"8","author":"Wild","year":"2005","journal-title":"Value Health"},{"issue":"5","key":"2019111808350836800_B9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2019111808350836800_B10","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"2019111808350836800_B11","volume-title":"EORTC QLQ-C30 Reference Values","author":"Scott","year":"2008"},{"issue":"12","key":"2019111808350836800_B12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3324\/haematol.11710","article-title":"Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?","volume":"92","author":"Efficace","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"2019111808350836800_B13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1191\/0962280204sm357ra","article-title":"Patient reported outcomes as endpoints in medical research.","volume":"13","author":"Fairclough","year":"2004","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"2019111808350836800_B14","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory.","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"2019111808350836800_B15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1200\/JCO.2005.02.8332","article-title":"Cancer symptom assessment instruments: a systematic review.","volume":"24","author":"Kirkova","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808350836800_B16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdl494","article-title":"Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making.","volume":"18","author":"Efficace","year":"2007","journal-title":"Ann Oncol"},{"issue":"12","key":"2019111808350836800_B17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428190500244183","article-title":"Quality of life in chronic lymphocytic leukemia: a neglected issue.","volume":"46","author":"Molica","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019111808350836800_B18","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1200\/JCO.2006.05.6929","article-title":"Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.","volume":"25","author":"Eichhorst","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808350836800_B19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2019111808350836800_B20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11899-010-0068-4","article-title":"Future therapies for the myeloproliferative neoplasms.","volume":"6","author":"Scherber","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"2019111808350836800_B21","article-title":"Longer-term follow up with TG101348 therapy in myelofibrosis confirms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden [abstract].","volume":"116","author":"Pardanani","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111808350836800_B22","article-title":"Phase 1\/2 study of SB1518, a novel JAK2\/FLT3 inhibitor, in the treatment of primary myelofibrosis [abstract].","volume":"116","author":"Verstovsek","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111808350836800_B23","article-title":"A Phase I\/II study of CYT387, an oral JAK-1\/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms [abstract].","volume":"116","author":"Pardanani","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/2\/401\/1342923\/zh802811000401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/2\/401\/1342923\/zh802811000401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:58:46Z","timestamp":1574067526000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/2\/401\/28465\/The-Myeloproliferative-Neoplasm-Symptom-Assessment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,14]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-01-328955","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,14]]}}}